| Code | CSB-RA006235MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Quetmolimab, designed for research targeting CX3CL1 (fractalkine), a unique chemokine that exists in both membrane-bound and soluble forms. CX3CL1 functions as both an adhesion molecule and chemoattractant, mediating the recruitment and adhesion of CX3CR1-expressing immune cells, particularly monocytes, natural killer cells, and T lymphocytes. This chemokine plays critical roles in inflammatory responses, atherosclerosis, neuroinflammation, and tumor microenvironment modulation. Dysregulated CX3CL1 signaling has been implicated in cardiovascular disease, neurodegenerative disorders, chronic kidney disease, and various cancers.
Quetmolimab represents a therapeutic antibody developed to inhibit CX3CL1-mediated signaling pathways. This biosimilar provides researchers with a valuable tool to investigate CX3CL1 biology, explore its involvement in inflammatory and immune-mediated diseases, and evaluate potential therapeutic interventions. The antibody enables studies examining chemokine-receptor interactions, immune cell trafficking, and the pathological consequences of CX3CL1 pathway activation across diverse disease models.
There are currently no reviews for this product.